Workers at drug maker Boehringer Ingelheim have begun ramping up a new $65 million pilot manufacturing plant on its Danbury-Ridgefield campus that will be used to make medicines still under development.

“We really needed a modern, state-of-the-art facility to replace our existing plant that was no longer scalable,” said James Baxter, senior vice president of development for the company. “The new plant was designed with enough room that we can install new technology as it becomes available.”

article in the Danbury News Times